The Role of Vitamin K Antagonists in Managing Thrombosis in Myeloproliferative Neoplasms
Long-term oral anticoagulation with vitamin K antagonists is recommended for most patients with myeloproliferative neoplasms experiencing thrombosis.
General Hematology
GENERAL HEMATOLOGY
FEATURE
LATEST NEWS
RBC Count, Erythrocyte Sedimentation Rate May Be Useful Biomarkers of Polycythemia Vera
Although some red blood cell-related parameters used in the diagnosis of PV may be misleading in the setting of iron-deficiency, RBC count may be an effective biomarker for PV when combined with ESR.
Salvage Therapy With Pegylated Interferon Alfa-2a Benefits High-Risk Myeloproliferative Neoplasms Previously Treated With Hydroxyurea
This nonrandomized study enrolled more than 100 patients with essential thrombocythemia or polycythemia vera resistant to or intolerant of hydroxyurea to determine if interferon alfa-2a is effective in these patients.
Gene Therapy Gets Orphan Drug Status for Gaucher Disease
An investigational gene therapy has been granted Orphan Drug designation from the Food and Drug Administration for the treatment of Gaucher disease.
Outcomes After Delaying Hematopoietic Stem Cell Transplantation in Children With Viral Respiratory Infections
Patients with viral respiratory infections exhibited poorer outcomes following transplantation compared with patients without infection.
Barriers to Patient Access to Allogeneic Hematopoietic Stem Cell Transplantation
Poverty was associated with lower rates of allogeneic hematopoietic stem cell transplantation, even after adjusting for race and rural residency.
Discussing Goals of Care With Oncologist, Earlier May Decrease Use of Intensive Health Care at End of Life
Patients with blood cancers were more likely to enroll in hospice earlier if they included a hematologic oncologist in their first discussion about their goals of care.
Differences in Obstetric Antiphospholipid Syndrome: Sydney Criteria vs Noncriteria Groups
Patients demonstrated similar rates of live births and thrombotic complications, but the most common complication was different for each group.
Global Need for Blood Products Outweighs Supply
Researchers found a 1.12 ratio of blood product need to supply, and 61% of countries included in the analysis had an insufficient supply of blood products.
Red Blood Cell Distribution Width May Be Prognostic for Survival in Light-Chain Amyloidosis
Red blood cell distribution width above the calculated cutoff of 13.8% was significantly associated with poorer overall survival.
Clinical Outcomes of Patients With AF and Contraindications to Oral Anticoagulation
Older patients with AF who have contraindications to oral anticoagulation because of high bleeding risk have increased mortality compared with untreated patients who have no contraindications.
Low-Dose Methotrexate May Decrease Symptom Burden in Myeloproliferative Neoplasms
In a retrospective service evaluation of patients with MPNs, researchers found that low-dose methotrexate eased symptom burden of comorbidities not related to the patient’s MPN.
Parents of Children With Cancer Benefit From a Novel Resilience Intervention: Results From the PRISM-P Trial
Results of the PRISM-P trial compared the benefits parents of children with cancer derived from resilience training in a 1-on-1 setting vs group setting vs usual psychosocial care alone.
Risks Associated With Reinitiating Antiplatelet, Anticoagulant Therapy After Gastrointestinal Bleeding
Patients who reinitated treatment less than a week after experiencing gastrointestinal bleeding experienced fewer ischemic events.
Current and Prospective Treatment Strategies for Myeloproliferative Neoplasms
Several novel treatment agents for myeloproliferative neoplasms are currently being studied in phase 1 or phase 2 trials.
Clinical Relevance of Key Genetic Mutations in Primary and Secondary Myelofibrosis
Researchers assessed patterns of genetic mutations and their prognostic effects in patients with primary and secondary myelofibrosis.
Prevalence of Hypertension Higher With Myeloproliferative Neoplasms Than in General Population
In this prospective study, researchers investigated the incidence of pulmonary hypertension among patients with MPNs. Their results led them to recommend systematic screening in this patient population.
Expert Panel Releases Recommendations on Unmet Clinical Needs With Ph-Negative Myeloproliferative Neoplasms
An overview of the findings of an expert panel that examined the unmet clinical needs for patients with Ph-negative MPNs to assess for risks of thrombosis.
Multidisciplinary Approach Maintains, Restores Fertility in Female Patients With Cancer
A report on oncofertility identifies the optimal multidisciplinary team for assuring that young patients with cancer can preserve their fertility and the options available to them for family building.
Challenges in the Diagnosis and Management of Polycythemia Vera
Due to conflicting literature, there is currently no consensus on the appropriate standard of care for managing polycythemia vera.
Familial Risks Associated With Hematologic Malignancies
Certain malignancies, younger age at diagnosis, and multiple affected relatives were all associated with increased familial relative risks.
Carfilzomib in Amyloid Light-Chain Amyloidosis When Bortezomib Is Contraindicated
Of 5 patients with amyloid light-chain amyloidosis who received carfilzomib, all achieved very good partial response or better.
American Board of Internal Medicine Announces New Option for Maintenance of Certification
The longitudinal assessment option would allow physicians to engage with medical knowledge and resources at their own pace.
New Treatment Option Approved for Patients With Myelofibrosis
The FDA has approved Inrebic (fedratinib; Celgene) capsules to treat adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.
Therapy With Sirolimus Could Prevent Graft-Versus-Host Disease After Stem Cell Transplant
Cumulative incidence of acute graft-versus-host disease within 100 days of transplant was 26% in the sirolimus group and 52% in the control group.
Levofloxacin Prophylaxis Least Disruptive to Gut Microbiome in Patients With Hematologic Malignancy
The use of levofloxacin as prophylaxis for the prevention of neutropenic fever and bloodstream infections was associated with less disruption of the gut microbiome in patients with hematologic malignancy.
Ruxolitinib Safe, Effective for Hydroxyurea Intolerant/Resistant Polycythemia Vera
An expanded treatment protocol study sought to validate the safety and efficacy of ruxolitinib, a JAK kinase inhibitor approved by the FDA for the treatment of polycythemia vera in patients who are intolerant of, or resistant to, hydroxyurea.
Prognostic Model for Patients With Systemic Immunoglobulin Light-Chain Amyloidosis and Renal Involvement
Researchers identified 3 prognostic factors predictive of all-cause mortality in multivariate analyses.
Nurses’ Guide to Managing Symptoms of Myeloproliferative Neoplasms
Oncology nurses discuss the importance of ongoing education on the treatments, symptoms, and available information on MPNs for patients, and oncology nurses.
Evans Syndrome: Incidence, Prevalence, and Survival
Patients with secondary Evans syndrome demonstrated increased mortality compared with all other cohorts.
Nipocalimab Gets Fast-Tracked for Hemolytic Disease of the Fetus and Newborn
The Food and Drug Administration (FDA) has granted Fast Track designation to nipocalimab (M281) for the prevention of hemolytic disease of the fetus and newborn (HDFN).
Do Oncologists Change Practice Based on Inadequate Evidence?
Oncologists are changing the way they treat, perhaps too quickly and with too little evidence — but the behavior may signal a bigger problem with how research is reported.
Stem Cell Transplantation and Long-Term Survival in Patients With Amyloid Light-Chain Amyloidosis
Overall survival of 15 years or longer was reached by 30% of patients with amyloid light-chain amyloidosis who underwent autologous stem cell transplant.
Symptom Burden in Polycythemia Vera Unrelated to Controlled Blood Counts
Patients with between 0, 1, 2, or 3 controlled blood counts reported similar scores on the symptom severity survey used in the study.
Depressive Symptoms May Be Associated With Survival in Patients With Hematologic Malignancies
According to a study published in Psycho‐Oncology, patients with newly diagnosed malignant lymphoma or multiple myeloma who reported depressive symptoms prior to the start of chemotherapy had poorer survival compared with patients who were not initially depressed. The prospective analysis was conducted at the Nagoya City University Hospital in Japan. Researchers sought to investigate the…
Gait Speed Effectively Predicts Clinical Outcomes in Older Patients With Hematologic Cancers
A decrease in gait speed by 0.1 m/s was associated with increases in mortality and utilization of emergency and acute care.
Type of EBV-Infected Cells Valuable in Diagnosis of Hematologic Disease
Determining the type of cell infected with Epstein-Barr virus (EBV) in peripheral blood mononuclear cells (PBMCs) proves to be a valuable tool for improving the differential diagnosis of hematologic disease with concurrent EBV infection, according to study results published in Open Forum Infectious Diseases. EBV is a herpesvirus that infects approximately 90% of the population…
EULAR Recommendations for Management of Henoch-Schönlein Purpura
A total of seven evidence based interdisciplinary recommendations for management of henoch-schönlein purpura have been formulated.
Number of Hematologic Complications of Immune Checkpoint Inhibitors Appears to Be Increasing
Hemolytic anemia and immune thrombocytopenic purpura were the most common complications of immune checkpoint inhibitor therapy.
Managing Essential Thrombocythemia in Pediatric Patients
Pediatric essential thrombocythemia is usually low risk; watching and waiting is a feasible management approach for asymptomatic patients.
Evaluating the Relationship Between Atrial Fibrillation and Cancer
Patients with atrial fibrillation and cancer may be at higher risk for thromboembolic events.
Combination Regimen for Pretransplant Conditioning May Improve Outcomes for Patients With Multiple Myeloma
Busulfan plus melphalan may be a viable pretreatment conditioning regimen for patients undergoing autologous hematopoietic stem cell transplantation.
Cerebrovascular Disease: A Serious Complication After Allogeneic Hematopoietic Stem Cell Transplantation
Patients who developed cerebrovascular disease following allogeneic hematopoietic stem cell transplantation experienced decreased survival.
Immunosuppression Tied to Poor Outcomes in Multiple Cutaneous SCC
Investigators estimated the effects of immunosuppression on poor outcomes in multiple cutaneous squamous cell carcinoma.
Navigating Cancer Communication on Twitter
Twitter is increasingly being used by oncologists as a tool to communicate advancements in in the treatment of cancer. What could go wrong?
Restoring T-Cell Immunity Following Allogeneic Hematopoietic Stem Cell Transplantation
Though adoptive T-cell transfer has demonstrated clinical applicability, many barriers prevent it from becoming a standard of care following transplant.
Alternative Antiepileptic Medications May Be Safe in Adults Receiving Allogeneic Hematopoietic Cell Transplantation
No difference was observed in relapse risk or survival between patients receiving phenytoin and patients receiving alternative antiepileptic medications.
Overcoming Challenges in Mechanical Circulatory Support: A Guide for Hematologists
Mechanical circulatory support (MCS) devices can lead to hemostatic events, making it crucial to include a hematologist on a patient’s MCS management team.
Quantifying Adherence to Mucormycosis Treatment Guidelines in Patients With Hematologic Malignancies
Adhering to mucormycosis treatment guidelines may be difficult for physicians because of the complexity of the disease.
Managing Neutropenic Sepsis in Patients With Cancer
Researchers found no evidence that neutropenic and non-neutropenic patients with sepsis should be treated differently.
Optimizing Transfusion in Patients With Hematologic Malignancies
Current transfusion recommendations do not adequately inform transfusion in patients with hematologic malignancies, who are increasingly treated as outpatients.
Want to read more?
Please login or register first to view this content.
